Clinical study of Shenqi Fuzheng injection combined with TC regimen in the treatment of advanced epithelial ovarian cancer
10.3760/cma.j.issn.1673-4904.2012.27.008
- VernacularTitle:参芪扶正注射液联合TC方案治疗晚期卵巢上皮癌的临床研究
- Author:
Wen ZHAO
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Drug therapy;
Shenqi Fuzheng injection
- From:
Chinese Journal of Postgraduates of Medicine
2012;35(27):22-25
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of Shenqi Fuzheng injection combined with TC regimen in the treatment of advanced epithelial ovarian cancer.Methods A total of 56 patients with advanced epithelial ovarian cancer were divided into treatment group and control group by random digits table method with 28 cases each.In treatment group,the patients received TC regimen (paclitaxel plus carboplatin) chemotherapy,while giving patients Shenqi Fuzheng injection in the process of chemotherapy.In control group,the patients only received TC regimen chemotherapy.Tcell subsets and NK cell changes,changes in the quality of life,the recent efficacy and toxicity were observed in two groups.Results CD3+,CD4+,CD4+/CD8+ and NK cell levels after treatment(0.6924 ± 0.0114,0.3738 ± 0.0234,1.48 ± 2.09,0.1849 ± 0.0210) were higher and CD8+ level (0.2528 ± 0.0112) was lower than those before treatment (0.6415 ± 0.0422,0.3254 ± 0.0312,1.02 ± 1.18,0.1378 ± 0.0126,0.3197 ± 0.0265 ) in treatment group (P ＜ 0.05).Compared with control group (0.6167 ± 0.0347,0.3125 ± 0.0334,1.01 ± 3.31,0.1241 ± 0.0324,0.3101 ± 0.0101 ),CD3+,CD4+,CD4+/CD8+,NK cell levels were increased and CD8+ was decreased in treatment group (P ＜ 0.05).The quality of life improvement in treatment group [60.7％ (17/28)] was higher than that in control group [32.1％ (9/28)] (P ＜ 0.05 ).There was no significant difference in the objective effective power between two groups [89.3 ％ (25/28) vs.82.1％ (23/28)] (P ＞ 0.05 ).The incidence of more than degree Ⅱ marrow depression (leucocyte decreasing,anemia,platelet decreasing) in treatment group was lower than that in control group [32.1％(9/28) vs.71.4％(20/28),25.0％(7/28) vs.42.9％(12/28),17.9％(5/28) vs.35.7％ (10/28)] (P ＜ 0.05).Conclusion Shenqi Fuzheng injection combined with TC regimen in the treatment of advanced epithelial ovarian cancer is safe and effective,it plays an important role in improving immune function,the quality of life and protecting bone marrow function of patients with advanced epithelial ovarian cancer.
